To review the literature to determine the sensitivity and specificity of gallium-68 prostate-specific membrane antigen (<sup>68</sup> Ga-PSMA) positron-emission tomography (PET) for detecting pelvic lymph node metastases in patients with primary prostate cancer (PCa), and the positive predictive value in patients with biochemical recurrence (BCR) after initial curative treatment, and, in addition, to determine the detection rate and management impact of <sup>68</sup> Ga-PSMA PET in patients with BCR after radical prostatectomy (RP).
The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging.
In this study we evaluated the diagnostic accuracy of <sup>68</sup>Ga prostate specific membrane antigen positron emission tomography/computerized tomography for detecting lymph node metastasis in patients with intermediate-high risk prostate cancer.
In this retrospective analysis, 116 patients who underwent <sup>68</sup>Ga-PSMA-11 PET/CT or MRI scans for staging of their intermediate or high-risk prostate cancer between April 2016 and May 2018 were included.
Performance and Impact of Prostate Specific Membrane Antigen-Based Diagnostics in the Management of Men with Biochemical Recurrence of Prostate Cancer and its Role in Salvage Lymph Node Dissection.
Currently, the use of prostate-specific membrane antigen (PSMA)-targeted radiotracers, e.g., <sup>99m</sup>Tc-labelled PSMA tracer analogues for radioguided surgery, is revolutionising prostate cancer surgery.
A prostate-specific membrane antigen (PSMA)-targeting ligand, armed with both an organotrifluoroborate and a metal-chelator (DOTA), was designed to optionally afford <sup>18</sup> F-, <sup>64</sup> Cu- or <sup>177</sup> Lu-labeled products that were injected into mice bearing prostate cancer (LNCaP) xenografts.
Ga-PSMA PET-CT allows accurate detection of lymphnodal metastases in patients with intermediate-risk and high-risk prostate cancer prior to definitive surgical treatment.
We developed prostate-specific membrane antigen (PSMA)-targeted low-molecular-weight (LMW) agents for <sup>212</sup>Pb-based TRT of patients with prostate cancer (PC) by evaluating the matching γ-emitting surrogate, <sup>203</sup>Pb.
The present study is based on a retrospective analysis of Gallium-68 (<sup>68</sup>Ga)-labelled prostate-specific membrane antigen (<sup>68</sup>Ga-PSMA I&T) PET/CT performed in newly diagnosed, treatment-naïve prostate cancer (PCa) patients prior to definitive treatment.
Dual-time point PET/CT scanning with [<sup>68</sup>Ga]Ga-PSMA-11 in the diagnosis of prostate cancer (PC) has been advanced as a method to increase detection of PC lesions, particularly at early stages of biochemical recurrence and as a potential means to aid the discrimination between benign and pathological prostate-specific membrane antigen (PSMA) uptake.
PSMA PET/CT should be considered to monitor PCa response to chemotherapy to detect early relapse, regardless of prostate-specific antigen levels, increasing the chances of finding low-volume oligoprogressive disease.
A total of 63 patients diagnosed with PCa who underwent (<sup>68</sup>Ga)PSMA 11 PET/CT between April 2019 and June 2019 and who had 5th minute and 1st and 2nd hour images were included in the study.
The aim of this study was to assess the added value of <sup>68</sup>Ga-PSMA-11 PET in predicting lymph node metastasis in men with intermediate- or high-risk prostate cancer.